These biomarkers data begin to illuminate bortezomib's mechanism of action in lymphoma.
2
Results: Thirty-one per cent of patients received bortezomib beyond first relapse.
3
However, apoptotic response to bortezomib was not affected by the deletion of p53.
4
Recently, it has been shown that bortezomib treatment enhances OB function.
5
The safety profile was consistent with that reported for single-agent bortezomib and romidepsin.
1
The inhibitors tested included several peptideboronates, some of which proved to be the most potent peptide-based inhibitors of beta-amyloid production reported so far.
Ús de ps-341 en anglès
1
TUNEL staining indicated that PS-341 treatment sensitizes Tax tumors to DNA fragmentation.
PSI suppressed the growth of AML cell lines more effectively than PS-341.
4
Both preclinical and clinical studies of novel agents including PS-341 and IMiDs are highlighted.
5
The tumor tissues treated with PS-341 show no consistent inhibition of NFkappaB activation in vivo.
6
Annexin V staining indicated that PS-341 response in vivo correlated with sensitivity to apoptosis induced by gamma irradiation.
7
However, the effect of PS-341 on the growth of tumors in Tax transgenic mice revealed heterogeneity in drug responsiveness.
8
Radiosensitization by PS-341 was reduced in fish with impaired p53 expression or function but not associated with enhanced expression of select p53 target genes.